Publications by authors named "Vimal H Prajapati"
Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.
Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.
Article Synopsis
- The Measure Up 1, 2, and AD Up studies assessed the effectiveness and side effects of upadacitinib for treating atopic dermatitis in adolescents aged 12-17 over a period of 76 weeks, extending the research beyond the previously available 52-week data.
- In a randomized clinical trial, participants received either upadacitinib (15 mg or 30 mg) or a placebo, with some receiving topical corticosteroids, allowing for varied analysis of its efficacy and safety.
- Results showed that a significant percentage of adolescents achieved a major improvement in their condition, with 89.1%, 84.4%, and 87.8% meeting the criteria for reduction in severity, showcasing the medication
Article Synopsis
- Safe and effective long-term topical treatments for atopic dermatitis (AD) are limited, leading to low adherence rates among patients.
- The study aimed to assess the efficacy and safety of once-daily roflumilast cream (0.15%) compared to a vehicle cream in patients aged 6 and older with mild to moderate AD across two phase 3 trials.
- Results showed that a significantly higher percentage of patients using roflumilast achieved treatment success and a notable reduction in eczema severity compared to those using the vehicle cream.
Considerations for defining and diagnosing generalized pustular psoriasis.
J Eur Acad Dermatol Venereol
September 2024
Article Synopsis
- Generalized pustular psoriasis (GPP) is a rare skin disease that causes painful bumps and redness all over the body, and it can be really serious if not treated.
- GPP can come and go, but sometimes the symptoms can last a long time, and it's important for doctors to know about it.
- This paper wants to help more people recognize GPP so that it can be diagnosed and treated faster.
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.
J Am Acad Dermatol
December 2024
Article Synopsis
- Alopecia areata (AA) is a hair loss disorder that significantly affects quality of life, and studies have shown that the JAK inhibitor deuruxolitinib can promote hair regrowth in affected individuals.
- A Phase 3 trial tested deuruxolitinib in adults aged 18-65 with severe hair loss, finding that a significant percentage of patients experienced notable improvements in hair regrowth compared to a placebo.
- Although the treatment was generally well-tolerated with mostly mild side effects, further research is needed to assess long-term safety and the effects of stopping the treatment.
Introduction: An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose combination halobetasol propionate (HP)/tazarotene (TAZ) lotion (HP/TAZ) in the treatment algorithm for plaque psoriasis.
Method: A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada.
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response.
View Article and Find Full Text PDFArticle Synopsis
- Atopic dermatitis (AD) significantly impacts quality of life due to intense itching and other symptoms; this study investigates the effects of the oral medication upadacitinib on patients with moderate-to-severe AD over 16 weeks.
- The analysis included data from 1,683 patients in clinical trials, showing that those taking upadacitinib experienced notable improvements in itching and other quality of life indicators compared to those on a placebo, starting as early as one week and continuing through the study period.
- Results indicated that patients on upadacitinib reported better outcomes in areas like skin pain, sleep, daily activities, emotional well-being, and overall treatment satisfaction, suggesting this medication could be an effective option for managing AD
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36.
View Article and Find Full Text PDFBackground: Dupilumab is approved for moderate-severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real-world data because providers have limited practical experience with this recently approved therapy.
Objectives: To describe the real-world effectiveness and safety in patients aged <12 years with moderate-severe AD currently receiving or previously having received dupilumab.
Methods: A multicenter retrospective study was conducted at six Canadian sites.
Background: Not much is known about the burden of palmoplantar pustulosis (PPP).
Objectives: To document the burden of PPP in Canada, and to compare with psoriasis vulgaris (PV).
Methods: Adult Canadians (excluding the province of Quebec) hospitalized or visiting an emergency department (ED) or hospital-/community-based clinic between April 1, 2007, and March 31, 2020, with a diagnostic code indicating PPP (ICD-10-CA: L40.
Background: The Psoriasis Longitudinal Assessment and Registry (PSOLAR) is a global, prospective, longitudinal, disease-based registry. It serves as a post-marketing safety commitment with a focus on patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Objectives: To describe the baseline disease demographics and clinical characteristics of a Canadian subgroup of participants enrolled in PSOLAR.